| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Lacto-N-fucopentaose I does not have a single defined molecular target. As a human milk oligosaccharide, it is thought to act as a decoy receptor, binding to pathogens and preventing them from attaching to host cells. Its antiviral activity is specifically linked to reducing the capsid protein VP1 to block virus adsorption. It also modulates cell cycle proteins by promoting CDK2 and reducing cyclin E.
|
|---|---|
| ln Vitro |
Lacto-N-fucopentose I (25-3200 μg/mL; 48 h) exhibits no hazardous reaction below 1600 μg/mL, but above 3200 μg/mL it exhibits some cytotoxicity [1]. For 14–18 hours, lacto-N-fucopentose I (25–1600 μg/mL) prevents EV71-infected RD cells from dying [1]. In EV71-infected RD cells, lacto-N-fucopentose I (100–400 μg/mL; 16 hours) dramatically decreased VP1 mRNA levels and ROS production at 400 μg/mL, leading to EV71-induced RD cells recovery from S phase arrest[1]. Lacto-N-fucopentose I (100 and 200 μg/mL; 3 days) dramatically lowers the levels of Egl-1, Ced-3, and Ced-4 and slows the apoptosis of Caenorhabditis elegans cells [1]. The amount of Micromonospora, Vibrio, Acidobacter, Gaelicella, Steroidobacterium, Variobacterium, Dactylosporium, RB41, Pir4_lineage, Pyridella, Haliangium, Roseiflexus, Pedomicrobium, and Bradyrhizobium can all be increased while the abundance of Sphingomonas, Stenotrophomonas, and Achromobacter can be decreased.
In vitro, Lacto-N-fucopentaose I exhibits antiviral and antibacterial activity. It reduces capsid protein VP1 to block virus adsorption. It promotes CDK2 and reduces cyclin E to recover cell cycle S phase block. Detailed IC50 values for these activities are not extensively reported in the available literature. |
| ln Vivo |
Detailed in vivo activity data for Lacto-N-fucopentaose I are not extensively reported in the available literature. As a human milk oligosaccharide, it is a component of breast milk and is believed to play a role in protecting infants from infections. Its antiviral and antibacterial properties suggest potential for in vivo efficacy.
|
| Enzyme Assay |
Non-cell-based assays for Lacto-N-fucopentaose I include binding assays to study its interaction with viruses and bacteria. Its ability to inhibit virus adsorption can be assessed by measuring its binding to viral capsid proteins. Its effects on cell cycle proteins could be studied in cell-free systems.
|
| Cell Assay |
Cell viability assay [1]
Cell Types: RD Cell Tested Concentrations: 25, 50, 100, 200, 400, 800, 1600 and 3200 μg/mL Incubation Duration: 48 h Experimental Results: Certain cytotoxicity was demonstrated at 3200 μg/mL , but no toxic reaction below 1600 micrograms/ml. RT-PCR[1] Cell Types: RD cells (infected with EV71) Tested Concentrations: 100, 200 and 400 μg/mL Incubation Duration: 16 hrs (hours) Experimental Results: VP1 mRNA levels were Dramatically diminished only at 400 μg/mL. Apoptosis analysis [1] Cell Types: RD cells (infected with EV71) Tested Concentrations: 100, 200 and 400 μg/mL Incubation Duration: 16 h Experimental Results: The early apoptosis rate was diminished to 10.9% ± 1.26% at 400 μg/mL mL, compared with 27.7% ± 2.13% in the untreated EV71 group. Dramatically inhibits the activities of caspase-3, caspase-8 and caspase-9. Restore diminished PAPR, NF-κB and Bcl-2 mRNA expression, and appropriately regulate Bad and Fas to normal levels. Cell cycle analysis [1] Cell Types: RD cells (infected with EV71) Tested Concentrations: 100, 200 and 400 μg/mL Incubation Duration: 12 h Experimental Results: Rescued EV71-induced S phase arrest, which promoted the transition of the G1 phase to the S phase. Cellular assays for Lacto-N-fucopentaose I are performed using virus-infected cell cultures. Cells are treated with the compound, and viral replication is assessed by measuring viral titers or the expression of viral proteins. The compound's ability to block virus adsorption is confirmed by pre-incubating the virus with the compound before adding it to cells. Its effects on cell cycle proteins (CDK2 and cyclin E) are assessed by Western blotting. |
| Animal Protocol |
In vivo animal models for Lacto-N-fucopentaose I would be required to assess its therapeutic potential. Based on its mechanism as an antiviral and antibacterial agent, relevant models could include models of viral or bacterial infection. The compound would be administered via appropriate routes, and pathogen burden and clinical signs would be assessed.
|
| ADME/Pharmacokinetics |
Lacto-N-fucopentaose I has a molecular weight of 853.77 g/mol and a molecular formula of C₃₂H₅₅NO₂₅. Its CAS number is 7578-25-8. The compound is a solid. Storage conditions: -20°C. The compound is supplied for research use only.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for Lacto-N-fucopentaose I are not extensively reported in the available literature. As a human milk oligosaccharide, it is generally considered safe. The compound is intended for research use only and is not for human consumption. Standard laboratory safety precautions should be followed.
|
| References | |
| Additional Infomation |
Lacto-N-fucopentaose I (LNFPI) is a human milk oligosaccharide (HMO) with antiviral and antibacterial activity. It reduces capsid protein VP1 to block virus adsorption and modulates CDK2 and cyclin E to recover cell cycle S phase block. Its CAS number is 7578-25-8.
|
| Molecular Formula |
C32H55NO25
|
|---|---|
| Molecular Weight |
853.77
|
| Exact Mass |
853.306
|
| CAS # |
7578-25-8
|
| PubChem CID |
53477883
|
| Appearance |
White to off-white solid powder
|
| LogP |
-9.3
|
| Hydrogen Bond Donor Count |
16
|
| Hydrogen Bond Acceptor Count |
25
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
58
|
| Complexity |
1290
|
| Defined Atom Stereocenter Count |
22
|
| SMILES |
C[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)O[C@@H]2[C@H]([C@H]([C@H](O[C@H]2O[C@@H]3[C@H]([C@@H](O[C@@H]([C@H]3O)CO)O[C@H]4[C@H]([C@H](O[C@H]([C@@H]4O)O[C@H]([C@@H](CO)O)[C@@H]([C@H](C=O)O)O)CO)O)NC(=O)C)CO)O)O)O)O)O
|
| InChi Key |
DTVXXTISAIGIBA-LDODJJGTSA-N
|
| InChi Code |
InChI=1S/C32H55NO25/c1-8-16(42)21(47)23(49)30(51-8)58-28-22(48)18(44)12(5-36)54-32(28)56-26-15(33-9(2)39)29(52-13(6-37)19(26)45)57-27-20(46)14(7-38)53-31(24(27)50)55-25(11(41)4-35)17(43)10(40)3-34/h3,8,10-32,35-38,40-50H,4-7H2,1-2H3,(H,33,39)/t8-,10-,11+,12+,13+,14+,15+,16+,17+,18-,19+,20-,21+,22-,23-,24+,25+,26+,27-,28+,29-,30-,31-,32-/m0/s1
|
| Chemical Name |
N-[(2S,3R,4R,5S,6R)-2-[(2R,3S,4S,5R,6S)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3R,4R,5R)-1,2,4,5-tetrahydroxy-6-oxohexan-3-yl]oxyoxan-4-yl]oxy-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
|
| Synonyms |
LNF I; LNF-I; Lacto-N-fucopentaose I
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1713 mL | 5.8564 mL | 11.7128 mL | |
| 5 mM | 0.2343 mL | 1.1713 mL | 2.3426 mL | |
| 10 mM | 0.1171 mL | 0.5856 mL | 1.1713 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
